Drug Trial Radar · NCT03083665
A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy
Last checked: Nov 20, 2026Latest source record: Oct 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
449
Actual
Start
Aug 22, 2017
Primary completion
Jun 30, 2022
Study completion Jun 30, 2022
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Mar 20, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to placebo (PBO) as adjunctive treatment in subjects (\>=16 to 80 years of age) with partial seizures with or without secondary generalization despite current treatment with 1 or 2 concomitant antiepileptic drugs (AEDs) and to assess the safety and tolerability of BRV in subjects \>= 16 years to 80 years of age.
Conditions
- Partial Seizures With or Without Secondary Generalization
- Epilepsy
Interventions
PlaceboDrug
* Pharmaceutical form: Film-coated tablets * Route of administration: Oral use
BrivaracetamDrug
* Pharmaceutical form: Film-coated tablets * Concentration: 25 mg tablets and 50 mg tablets * Route of administration: Oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From start of the Treatment Period (Week 0) until Safety Visit (up to Week 18); only for OLTP- From last visit of Transition Period to beginning of MAP (up to 4 Years 10 Months)
- Percentage of Participants With Treatment-Emergent AEs (TEAEs) Leading to Study WithdrawalTime frame: From start of the Treatment Period (Week 0) until Safety Visit (up to Week 18); only for OLTP- From last visit of Transition Period to beginning of MAP (up to 4 Years 10 Months)
- Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)Time frame: From start of the Treatment Period (Week 0) until Safety Visit (up to Week 18); only for OLTP- From last visit of Transition Period to beginning of MAP (up to 4 Years 10 Months)
- Partial Seizure Frequency Per 28 Days During the 12-week Treatment PeriodTime frame: From Baseline to 12-week Treatment Period
Locations
94 sites in 7 countries. Site status is shown where the registry gives one.
Ep0083 905
Beijing, China
Ep0083 906
Beijing, China
Ep0083 907
Changchun, China
Ep0083 901
Chengdu, China
Ep0083 902
Guangzhou, China
Ep0083 909
Guangzhou, China
Ep0083 917
Guangzhou, China
Ep0083 920
Guangzhou, China
Ep0083 922
Guangzhou, China
Ep0083 924
Guangzhou, China
Ep0083 912
Hangzhou, China
Ep0083 908
Lanzhou, China
Ep0083 921
Nanchang, China
Ep0083 926
Pingxiang, China
Ep0083 910
Shijiazhuang, China
Ep0083 925
Suzhou, China
Ep0083 913
Wenzhou, China
Ep0083 927
Xi'an, China
Ep0083 930
Xinxiang, China
Ep0083 916
Yinchuan, China
Ep0083 918
Zhanjiang, China
Ep0083 904
Zhengzhou, China
Ep0083 923
Zunyi, China
Ep0083 148
Adachi-ku, Japan
Ep0083 116
Asaka, Japan
Ep0083 126
Bunkyō City, Japan
Ep0083 127
Bunkyō City, Japan
Ep0083 146
Chiba, Japan
Ep0083 122
Hachinohe, Japan
Ep0083 111
Hamamatsu, Japan
Ep0083 141
Higashisonogi-gun Kawatana-cho, Japan
Ep0083 110
Hiroshima, Japan
Ep0083 121
Itami, Japan
Ep0083 102
Kagoshima, Japan
Ep0083 142
Kamakura, Japan
Ep0083 140
Kawasaki, Japan
Ep0083 123
Kodaira, Japan
Ep0083 115
Kokubunji, Japan
Ep0083 132
Kōriyama, Japan
Ep0083 112
Kōshi, Japan
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.